[Targeting TNF receptors in cancer therapy: toward a new role for LIGHT and HVEM]
Christine Pasero1, Daniel Olive
1Centre de recherche en cancérologie de Marseille, université de Méditerranée, IFR 137, institut de cancérologie et d'immunologie de Marseille, Inserm UMR599, 27, boulevard Leï-Roure, 13009 Marseille, France.
Abstract:
In spite of recent advances in cancer therapy, some tumors still remain incurable and novel therapeutic approaches need to be developed. Apoptosis is a cell death inducing mechanism and is actually one of the most obvious targets for cancer treatment. It becomes clear that this regulation is more complex than previously expected, and multiple signalling pathways for cell death have to be considered. Agents with the property of inducing tumor cell death, such as TNF/TNFR superfamily members, also called "death receptors", represent an attractive therapeutic approach. Our team identified another member of this family, HVEM and its ligand LIGHT, as promising therapeutic targets. HVEM was known as a costimulatory molecule, but this role is getting more complex with the identification of new ligands and the highlights of new functions. So, HVEM could combine a pro-apoptotic effect with the immune system activation. This review will first focus on mechanisms and new insights in therapeutic application of TNF receptors. Then we will present new functions for LIGHT and HVEM and how these functions may provide new opportunities for antitumoral therapy and more effective treatments.
Insights
Novel cancer therapies targeting tumor cell death are crucial. This review explores Tumor Necrosis Factor (TNF) receptor superfamily members, specifically HVEM and LIGHT, as promising targets for inducing apoptosis and activating the immune system against cancer.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Context:
- Despite advances in cancer therapy, some tumors remain incurable.
- Apoptosis (programmed cell death) is a key target for cancer treatment.
- TNF/TNFR superfamily members, or 'death receptors', are attractive therapeutic agents.
Purpose:
- To review mechanisms and therapeutic applications of TNF receptors.
- To present novel functions of LIGHT and HVEM.
- To explore opportunities for antitumoral therapy using these targets.
Summary:
- HVEM (Herpesvirus entry mediator) and its ligand LIGHT are identified as promising therapeutic targets within the TNF superfamily.
- HVEM exhibits a dual role, potentially inducing apoptosis and activating the immune system.
- Understanding these complex functions can lead to more effective cancer treatments.
Impact:
- Highlights new therapeutic strategies for incurable tumors.
- Provides insights into the complex regulation of cell death pathways.
- Offers potential for developing novel antitumoral therapies by combining apoptosis induction and immune activation.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...


